|Cancer Stem Cell News 5.40 October 12, 2016|
Investigators showed that dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) is a novel negative regulator for formation of breast cancer stem cells. [Oncogene]
CD133 is a potential target for accurate diagnosis of glioblastoma, which could improve its poor prognosis for patients when cancer stem cells are present. Scientists designed a small peptide-based imaging agent with stimulus-responsive properties. [Acta Biomater]
The authors demonstrated that Musashi 2 (MSI2) was highly expressed in liver cancer stem cells (CSCs). Overexpression or knockdown of MSI2 altered CSC-related gene expression, self-renewal as well as resistance to chemotherapy in HCC cell lines. [Cancer Lett]
The recent identification of “Side Population” (SP) cells in a number of unrelated human cancers has renewed interests in the hypothesis of cancer stem cells. Scientists isolated SP cells from HepG2 cells and 18 of the 21 fresh hepatocellular carcinoma tissue samples. [Sci Rep]
DUOX1 silencing in H292 cells led to enhanced resistance to epidermal growth factor receptor tyrosine kinase inhibitors such as erlotinib, and enhanced levels of cancer stem cell (CSC) markers CD133 and ALDH1. Furthermore, acquired resistance of H292 cells to erlotinib resulted in enhanced epithelial-to-mesenchymal transition and CSC features, as well as loss of DUOX1. [Oncogenesis]
It remains unknown whether cell surface vimentin (CSV) can serve as a therapeutic target in CSV-expressing tumor cells. The authors found that CSV was present on glioblastoma multiforme (GBM) cancer stem cells and that CSV expression was associated with spheroid formation in those cells. [Oncotarget]
Investigators discovered that a non-anticoagulant heparan sulfate hexasaccharide sequence, but not other shorter or longer sequences, selectively inhibited cancer stem cell (CSC) self-renewal and induced apoptosis in colorectal, pancreatic, and breast CSCs suggesting a very general phenomenon. [Oncotarget]
An alternative method for research of gliomagenesis and drug resistance is to use in vitro tumor model that closely mimics the in vivo tumor microenvironment. Investigators established a 3D bioprinted glioma stem cell model, using modified porous gelatin/alginate/fibrinogen hydrogel that mimics the extracellular matrix. [Biofabrication]
Scientists investigated the cytotoxic activity of tingenin b against breast cancer stem cells (stem-cell enriched population from MCF-7 cell line, MCF-7s). They have found that tingenin b was cytotoxic against MCF-7s by inducing apoptosis. [Chem Biol Interact]
The authors explore an emerging concept that lysine acetyltransferase enzymes drive cellular plasticity in the context of somatic cell reprogramming and tumorigenesis. [J Mol Biol]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Cellerant Therapeutics, Inc. announced preclinical data showing potent killing of leukemic blast and stem cells by CSC030-ADC, the company’s antibody drug-conjugate (ADC) product candidate being developed as a treatment for acute myeloid leukemia. [Press release from Cellerant Therapeutics, Inc. (BusinessWire Inc.) discussing research presented at 7th Annual World Antibody Drug Conjugate (ADC) Meeting, San Diego]
Bristol-Myers Squibb Company announced updated results from the Phase I CheckMate -016 trial, which evaluated the safety and tolerability of Opdivo at different doses as part of a regimen with Yervoy, sunitinib or pazopanib in previously treated and treatment-naïve patients with metastatic renal cell carcinoma. [Bristol-Myers Squibb Company]
Daiichi Sankyo Company, Limited and the Dana-Farber Cancer Institute announced a preclinical research collaboration focused on lung cancer. [Daiichi Sankyo Company, Limited]
Daiichi Sankyo Company, Limited announced that the first patient has been enrolled in the global Phase III QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients with newly-diagnosed FLT3-ITD-positive acute myeloid leukemia. [Daiichi Sankyo Company, Limited]
Delcath Systems, Inc. announces that five clinical sites in Europe have been activated and are open for patient enrollment in the company’s FOCUS Phase III clinical trial for patients with hepatic dominant ocular melanoma. [Delcath Systems, Inc.]
A recruitment and retention program launched by the Howard Hughes Medical Institution in Chevy Chase, Maryland, aims to reduce barriers for women and under-represented minorities who seek academic-research careers in the life sciences. [Nature Careers]
A prominent developer of drugs that use RNA interference has abandoned one of its leading candidates amid safety concerns — sending a fresh wave of worry through a field that has long struggled to bring treatments to market. [Nature News]
Finding the right grant or fellowship to fund a postdoc can be a challenge, and the situation is all the more complex in Europe, where academic systems, career prospects, and living costs vary widely among countries. [Science Careers]
NEW Cancer Metabolism and the Tumor Microenvironment Conference
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 5.40 | Oct 12 2016